The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) - Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) - Vildagliptin, with Metformin.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3pGUrtM
via IFTTT
0 comments:
Post a Comment